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for responding to mass trauma and disaster emphasize the impor-
tance of focusing on resilience. In the immediate and ongoing re-
sponse, consensus guidelines emphasize the importance of
interventions that maintain calm, build community, and sustain
hope [3,4].er the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2 N.A. Fineberg et al. / Comprehensive Psychiatry 100 (2020) 152174That said, it is important to provide appropriate attention to specific
psychiatric conditions that may be initiated or exacerbated by disaster.
Perhaps no group of individuals with mental illness is as directly af-
fected by theworsening outbreak of COVID-19 as people livingwith ob-
sessive-compulsive disorder (OCD). Paradoxically, they are ‘experts by
experience’ in attempting to avert dangers through enacting compul-
sive behaviours. Chiefly, the spike in anxiety about the virus is fuelling
existing obsessive fears of contamination in some people with OCD
and further triggering harmful compulsive actions. For these people, co-
ronavirus can become all they think about [5]. Indeed, some patients
with contamination-related OCD are expressing doubts about the ratio-
nality of the therapies they have been pursuing. Several patients have
told their clinicians they were “right all along”, as now everybody
looks like them. For others, COVID-19 is likely to cast a long shadow,
as people of all ages with OCD are known to be particularly inflexible
at ‘unlearning’ danger responses when they become obsolete [6,7] and
thereby conditioned to prolonged virus-induced distress and anxiety.
In response to the emerging crisis and growing calls from patients
and clinicians for guidance [5], a working group of clinical experts
from the International College of Obsessive Compulsive Spectrum
Disorders (ICOCS) and the Obsessive-Compulsive and Related
Disorders Research Network of the European College of
Neuropsychopharmacology (OCRN) have produced this consensus
statement with the aim of delivering pragmatic guidance at the ear-
liest opportunity to clinicians for managing this complex challenge.
The advice is largely based on empirical evidence, including the clin-
ical experience gained from working in specialised OCD treatment-ser-
vices before and during the pandemic. Our group of international
experts includes a balanced representation of genders, including clini-
cians treating child, adolescent and adult patients, with additional con-
tributions from individuals with lived experience of the disorder and
early career scientists. Once agreement was reached on the key issues
to be covered, in a series of online discussions, an initial draft was pre-
pared and circulated iteratively among the authors and edits were se-
quentially incorporated. The final report covers the key issues judged
by our group of experts to be of most relevance for clinicians for the
treatment of OCD under COVID-19 conditions. Although preliminary,
based on the ‘precautionary principle’ it was considered a priority to re-
lease guidance at the earliest opportunity, on the understanding that it
may be updated as new information arises.
The guidance to clinicians is as follows:
1. Take a compassionate calming approach. Use telemedicine including
telephone or video calls. Be aware that the pandemic is affecting
countries with different cultural environments and different avail-
able resources to deal with it. For example, in regions of Latin Amer-
ica and in Africa lack of water and access to the Internet, and poverty
levels greater than 50%make it hard to stay at home, since there is no
monetary support from the government to aid survival.
2. Careful history taking. Confirm the diagnosis of OCD, paying particu-
lar attention to other obsessive-compulsive and related disorders
(OCRDs) including hypochondriasis (recently endorsed as an OCRD
in theWorld Health Organization (WHO) ICD-11) [8], as these disor-
ders are likely to be most affected by COVID-19. Clarify the extent to
which the current symptoms represent a rational or exaggerated re-
action to recent highly stressful events, or a worsening of obsessive-
compulsive symptomatology. Establish the level of insight into the ir-
rationality or excessiveness of the symptoms, and thepresence or ab-
sence of tics, as these may influence the care plan. Note that many
OCD patients may not experience exacerbation of their OCD. On the
other hand, patients who have experienced contamination symp-
toms in the past may find that they re-experience contamination
fears and cleaning or washing compulsions under the conditions of
the pandemic. It is also important not to assume that every patient
with contamination fears related to germs and illnesswill necessarily
be excessively concerned about COVID-19. The focus of concerns inthose with OCD is often idiosyncratic, and some individuals, for ex-
ample, may have greater fears of a sexually transmitted disease or
an antibiotic resistant infection.Manywill, however, have significant
exacerbation of contamination or illness concerns, or comorbid con-
ditions that haveworsenedwith stress (such as anxiety disorder, de-
pression or bipolar disorder, or even post-traumatic stress disorder
(as reported after the SARS epidemic)) thatmay need to bemanaged
separately in order to prevent decline in level of functioning. Indeed,
OCD comorbidity can become particularly problematic, especially if
patients have, or have previously shown, cleaning or washing symp-
toms. Where OCD and related disorder is not the principal diagnosis
for clinical attention, please refer to other guidelines. In particular,
noteWHO ICD-11 guidelines regardingmental health and psychoso-
cial considerations during the COVID-19 outbreak [1].
3. Assess suicidal risk. Even though OCD has not been considered a dis-
order with high risk for suicide, recent studies have shown that some
patients, including those with severe obsessions, comorbid depres-
sion, bipolar disorder, impulse control disorders, substanceuse disor-
ders, personality disorders and eating disorders may be at increased
risk [9]. Additional COVID-related factors found anecdotally to poten-
tially increase suicidal risk include a recent increase in OCD severity,
experiencing a family member found positive for COVID-19 or find-
ing the effects of quarantine or isolation distressing. For all patients
with OCD, but particularly in such cases, consider actively evaluating
the suicide ideation and risk through specific questions and instru-
ments (e.g., the Columbia Suicide Severity Rating Scale [10] or simi-
lar) and hospitalize the patient if needed.
4. Provide psychoeducation with balanced information about the
known risks and impact of COVID-19 on physical and mental health.
This includes the difficulties managing uncertainty associated with
the virus, which almost everyone is experiencing right now but
thatmight be particularly challenging for somepeoplewith OCD, hy-
pochondriasis or anxiety. Highlight the need for physical distancing
(staying at home except for essential tasks like grocery shopping),
with special precautions for the elderly. Patients need to understand
that this health crisis may well persist for some time, and they need
to manage their stress levels over time (e.g., by putting into play
long-term routines of mindfulness techniques, exercise and
structure).
5. Enquire about Internet usage and news consumption; some patients
are spending hours a day watching television and online media
sources, whichmay be significantly exacerbating their OCD and anx-
iety. Offer a balanced approach (e.g., individuals should not spend
more than an hour a day [a half-hour in the morning and a half-
hour at night] to stay informed about the pandemic, to minimize
the triggering of symptoms). Suggest trusted sources to avoid
myths, rumors and misinformation. You may wish to refer the pa-
tient to the relevant health education websites of the WHO
(https://www.who.int/health-topics/coronavirus), the Centers for
Disease Control and Prevention (CDC) (https://www.cdc.gov/
coronavirus/2019-ncov/infection-control/hcp-hand-sanitizer.html),
or the Center for Health Security, Johns Hopkins University (http://
www.centerforhealthsecurity.org/resources/COVID-19/index.html).
Handwashing videos may be helpful to guide patients about what is
appropriate and discourage unnecessary excess. For example, the
National Health Service (https://www.nhs.uk/video/pages/how-to-
wash-hands.aspx) and CDC videos https://www.youtube.com/
watch?v=3EoAyQu3LIs) recommend handwashing for 20 s; thus,
anything beyond this is likely to be compulsive and excessive.
6. If OCD symptoms are the main problem:
I. Review medication status as a priority: Based on the risks associ-
ated with exposure and response prevention (ERP) in the pan-
demic (see below), and uncertainty as to which of the two
evidence-based treatments, pharmacotherapy or cognitive behav-
iour therapy (CBT), represents the most efficacious first line treat-
ment modality [11], pharmacotherapy should be the first option
3N.A. Fineberg et al. / Comprehensive Psychiatry 100 (2020) 152174for adults and children with OCD with contamination, washing or
cleaning symptoms during the COVID-19 pandemic. Consider A)
type of medication; most patients should receive an SSRI, or if not
responsive, another SSRI and as a third choice clomipramine (for
which an ECG may be required in certain patient groups); Note
US Food and Drug Administration "black box" warnings or advice
fromequivalent national regulatory authorities regarding increased
risk in young people and other vulnerable patient groups. Check for
adverse effects and be available for any concerns related to "activa-
tion" or newly emergent or increased suicidal ideation,which in the
young can be mitigated by starting treatment at a low dose and ti-
trating more gradually; B) dosage; if the patient is on a suboptimal
dose, consider increasing it, paying attention to any contraindica-
tions; C) SSRI-resistance; consider a low dose of adjunctive antipsy-
chotic (aripiprazole, risperidone, quetiapine, olanzapine),
especially if a tic is present; D) adherence; ensure the patient is
able to obtain an adequate supply and is taking the treatment reg-
ularly. In caseswhere adherence is problematic, especially if insight
is poor or there are executive dysfunction deficits, it may be neces-
sary to provide additional support either from clinical support staff
or the family to ensure adherence. The use of Medi Pill Organisers
(dosette boxes) and tools such medisafe (free application that
aids patients to remember to take medications and sends reports
to the psychiatrist) canbe helpful tomonitor adherence; E)manage
sleep disturbancewhen present, as healthy sleep contributes to im-
mune function and enhances anxiety management.
II. Review and risk assess the CBT plan: Considerations include
whether it is feasible in the pandemic situation, and specifically
whether it fits with government safety guidance. In many coun-
tries, psychotherapy services are being dramatically cut back as
staff is redeployed to cover emergency care. Consider that it can
be difficult to disentangle OCD-related cleaning and checking com-
pulsions from rational COVID-19-related safety behaviours and to
devise ERP strategies that are coherent and robust. Moreover, as
COVID-19 is highly contagious, and patients can easily be confused
by exposure exercises, particularly during the early stages of ther-
apy or when practising exposure on their own at home, the risk of
patients becoming seriously infected with the coronavirus could
be increased. This risk becomes even more true for children
whose knowledge base and judgment is not yet matured.
We therefore recommend significantly tailoring CBT to take into
account the CDC guidance (e.g., hand washing for 20 seconds
with soap and water rather than ceasing hand washing
completely). However for OCD patients with contamination fears
and cleaning or washing compulsions, active and in vivo CBT
with exposure and response prevention (ERP) will need to be sen-
sibly adapted and may need to be paused. This specifically relates
to active, in vivo exposure aimed at tackling contamination. In-
stead we suggest using therapist time to support patients and try-
ing to prevent them from deteriorating, e.g. by encouraging them
to restrain their compulsions as far as possible, rather than directed
at actively treating contamination fears and concentrating on tech-
niques such as behavioural activation and activity scheduling
which can assist in preventing deterioration and helpwith depres-
sive symptoms [12]. Indeed, activity scheduling can be particularly
useful as a form of CBT at this time. Obsessions often expand to fill
a vacuum of time and keeping busy is particularly important as a
means of staying well. Patients can be asked to fill out an activity
schedule diary in advance, making sure that they have a balance
between activities which may give them a feeling of mastery as
well as those for pleasure (see below) [13].
For clinicians working in specialist centers, other less evidence-
based forms of CBT not involving ERP, such as imaginal exposure
or danger ideation reduction therapy, could potentially be offered
for patients with contamination – related OCD, even when their
concern is COVID. This should be considered on a case-by-casebasis and only done if the patient has good insight, is willing, and
is stable enough to do so. It would need to be made clear that the
efficacy of this form of treatment is not as well established and it
should not be viewed as a substitute for in vivo ERP when post
pandemic restrictions are lifted.
For those patients whose exposures are not contamination related,
many ERP treatment plans could be continued (e.g. addressing
urges to check, obsessive thoughts of harm, symmetry/order ob-
sessions), especially those that can be done at home, and as long
as they are within CDC recommended precautions such as main-
taining physical distancing. Once again it is important to remem-
ber that even if the OCD does not focus on contamination fears,
the physical distancing can increase symptoms of anxiety and de-
pression. ERP increases distress and can also temporarily increase
depression and so the patient's mental state must be monitored
carefully.
Keeping people calm and reducing the risk of depression using
supportive techniques is an essential element of care. Neverthe-
less, the clinician should still try to find ways to help the patient
foster resilience towards obsessional thinking and compulsive
acts. Thus, extreme behaviours should be discouraged along with
mental compulsions. Avoidance and accommodation should be
assessed carefully to determine whether it is proportional to the
current situation and addressed carefully to prevent backsliding.
We suggest therapists should regularly check e.g. by phone or dig-
itally, those OCD patients likely to engage in particularly harmful
decontamination rituals or behaviours. The use of video calls
with the patients should be recommended, where possible. The
added benefit of video calling is that it helps the therapist perform
a visual risk evaluation, which is especially valuable for patients
living alone, to determine the condition of the patient's hands,
presence of food in the fridge or cupboard, etc. One group of pa-
tients requiring particularly vigilant care is those who, as a result
of doubt or uncertainty about whether food in the house is con-
taminated, respond by throwing everything away and conse-
quently have little or no food in the house. Identify and
discourage high-risk obsessive-compulsive behaviours, such as
washing in boiling (very hot) water or bleach, or total fasting. On
the contrary, encourage eating and drinking to maintain health.
III. Deep brain stimulation (DBS): For this small group with ex-
tremely severe, treatment resistant illness, a moderate increase
of psychological distress or OCD symptomsmay be expected dur-
ing the pandemic, but this does notmean that DBS is not working.
We recommend delaying the implantation of electrodes in those
OCD patients waiting for DBS until the outbreak is over. In those
who have electrodes implanted, a worsening of OCD symptoms
may be experienced if the battery stops working. Such patients
should be encouraged to check with their treating clinician in
case the power has simply been turned off, or if there is a real
need for battery replacement. If the latter, a balance between
risks and benefits should be evaluated in each case and consider-
ation given to whether the replacement procedure may be de-
layed to reduce the increased risk of being exposed to COVID-19
in hospital.
IV. Social and occupational care: There is great value in activity sched-
uling and establishing a daily routine, even if stuck at home. Pa-
tients under quarantine or staying at home under national
restrictions are at great risk of circadian rhythm disruption. Circa-
dian rhythms disruption could increase anxiety and worsen OCD
symptoms while regular circadian rhythms and regular physical
activity are relevant in order to reduce anxiety or alarm levels
and therefore achieve better control of OCD symptoms. Therefore
it is recommended to respect a regular awakening time and bed-
time every day and to regularly perform some physical activity
in the morning especially in a bright room. Finally it is recom-
mended to avoid late-night dinners so as not to affect sleep quality.
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to news as a distraction to occupational or preferred activities, pro-
vide acknowledgement of fear but also a balanced perspective on
risk, address grief and loss of control and recommend hedonic ac-
tivities especially those that involve children, such as baking,
cooking, gardening, inventing a new game or watching a movie.
Help the isolated patient to overcome loneliness and build stability
by increasing communication with friends, family members and
loved ones, even if at a distance via the multiple online platforms
including Facetime; Skype and Zoom. Learning to use these can
be a helpful experience in terms of the acquisition and mastery
of new skills as well as the pleasure of social contact. In the case
of those with a poor social network, telephone helplines such as
those run by OCD charities are particularly useful, especially if
managed by qualified trained professionals.
Also encourage patients and family members to keep weight
under control e.g. by creating new places for sports in the home
and including physical activity in their home routine. Exercise
can be additionally helpful for some patients copingwith themen-
tal effects of the pandemic. Aerobic exercise has in some studies
been shown to have positive effects for those with depression,
anxiety [14,15] and OCD [16]. Where there is ability to go out for
aerobic exercise once a day then a brisk walk or run can be useful.
Some excellent videos are available online (e.g. using home-based
workout exercises that are freely available on YouTube or other
mobile apps), demonstrating aerobic exercises that can be per-
formed in a limited space. Gyms and yoga centers are fuelling
the drive to stay active by offering online exercise classes, some
free of charge, or extending trial periods for at-home workouts.
V. Carer support: Remember that family members and caregivers of
patients with OCD are also at increased risk of developing stress re-
lated disorders owing to the worsening of patients' symptoms and
may need additional support in their own right. Parents of children
with OCD are likely to require even more coaching and support
than before, especially as relationships may be impacted in unpre-
dictable ways by the fact that parents and children are spending so
much time together. Consider that parents are burdened differently
under COVID-19, especially single parentswhomay be heavily bur-
dened or those with little living space, especially if children are be-
coming irritable or aggressive (as is often the case for childrenwith
OCD if their behaviours are not accommodated).
Parents and children should be encouraged to maintain social con-
tact with their environment via the Internet or phone for distrac-
tion and support. Rules for dealing with possible conflicts and
tantrums should ideally be established in advance. Parents should
not only focus on the problems connected with the current pan-
demic situation but be encouraged to engage in joyful activities
with their child instead. Especially in a quarantine situation it is im-
portant to make clear that not all aspects of life are determined by
the coronavirus or OCD. Staying hopeful and together seems one of
the most important points (especially for parents, acting as role
models for their children), and increased family togetherness
may be a “silver lining” in the pandemic.
We are aware this guidancemarks a change in practice for many cli-
nicians treating OCD. Temporarily modifying or pausing in vivo CBT
with ERP for contamination-related OCD, which is an effective form of
treatment often preferred by patients in normal times, is a difficult de-
cision to make, but as with any treatment, the benefits and risks need
to be balanced up and clear messages that take public health into ac-
count need to be given at this time of heightened risk of infection, to
avoid confusion. On the other hand, many forms of CBT can be contin-
ued with modification for safety as needed. We believe that under
COVID-19, stringent efforts should be made to provide effective care
for individuals with OCD and that the best available treatments formost patients are likely to include providing evidence-based pharmaco-
therapy and modifying or pausing CBT in conjunction with enhanced
supportive therapies including social and occupational care. Under-
standing the impact of a pandemic like COVID-19 on the expression of
OCD in affected patients, and on the development of new cases of
OCD, is likely to provide important insights into the environmental de-
terminants of the disorder. We consequently urge research-active
groups to engage in investigating the impact of such changes on health
outcomes among their patients, as well as initiatives to explore the ex-
pected rise in incidence of OCD once the pandemic is over.Conflicts of interest and source of funding
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